The rising popularity of GLP-1 drugs could cause all kinds of ripple effects. According to one estimate, 9% of the U.S. population could be on Ozempic or similar medications by 2030. Meanwhile, drugmakers are already developing the next generation of weight-loss drugs and researchers are studying the possible health benefits beyond weight loss and diabetes, including addiction. In the final episode of our series we ask: What could all this development mean for businesses, from the food sector to airlines? And who wins and who loses in the post-Ozempic economy? Guests include: David Ricks, CEO of Eli Lilly; and Mehdi Farokhnia, an addiction researcher at the National Institutes of Health. Listen to Episodes 1, 2 and 3 of “Trillion Dollar Shot” here. Learn more about your ad choices. Visit megaphone.fm/adchoices